Table 7:
Outcomes of PRN Re-treatment and A-VEGF and Photodynamic Combination Intervention Trials
| Study Arm | Δ ETDRS BCVA Letters Mean ± SD | Proportion (%) Gaining ≥ 15 Letters | Proportion (%) Losing ≥ 15 Letters | Δ CRT Mean (μm) | Injections Mean ± SD (Interval) | Proportion Injection Free-Interval ≥ 3 Months (95% CI) |
|---|---|---|---|---|---|---|
| DENALI (52) | ||||||
| Sham PDT + 0.5 mg of ranibizumab monthly | 8.1 ± 15.1 | 41.1 | 8.4 | –172.2 ± 166.7 | 7.6 (months 3–11) | NA |
| SF-PDT + 0.5-mg 3MoLD of ranibizumab and PRN | 5.3 ± 15.7 | 31.3 | 8.4 | −151.7 ± 135.6 | 2.2 (months 3–11) | 92.6% (85.4–97.0) |
| RF-PDT + 0.5-mg 3MoLD of ranibizumab and PRN | 4.4 ± 15.5 | 24.7 | 11.8 | –140.9 ± 135.6 | 2.8 (months 3–11) | 83.5% (74.6–90.3) |
| MONT BLANC (54) | ||||||
| Sham PDT + 0.5-mg 3MoLD of ranibizumab and PRN | 4.4 ± 15.9 | 25.8 | 9.1 | 107.7 ± 11.02 | 2.2 (months 3–11) | 92% |
| SF-PDT + 0.5-mg 3MoLD of ranibizumab and PRN | 2.5 ± 14.8 | 18.2 | 13.2 | –115.3 ± 9.04 | 1.9 (months 3–11) | 96% |
| Williams et al (57) | ||||||
| 0.5-mg 3MoLD of ranibizumab and PRN | 9.9 ± 23.9 | 33 | 22 | –92.5 ± 111.26 | 3.8 (9 months) | – |
| RF-PDT + 0.5-mg 1MoLD of ranibizumab and PRN | 2.6 ± 18.5 | 14 | 31 | –106.7 ± 94.12 | 2.0 (11 months) | – |
| Krebs et al (53) | ||||||
| 0.5-mg 3MoLD ranibizumab and PRN | 5.1 | NR | 9.1 | –81.49 | 6.3 | – |
| PDT + 3MoLD of ranibizumab and PRN | –7.1 | NR | 31.6 | –138.2 | 4.7 | – |
| Rudnisky et al (55) | ||||||
| 1.25-mg 1MoLD of bevacizumab | 5.1 | 33.8 | 25.9 | NR | 3.32 ± 1.71 (R, 1–8) (0–12 months) | – |
| RF-PDT + 1.25-mg 1MoLD of bevacizumab | 4.8 | 39.0 | 19.9 | NR | 3.14 ± 1.52 (R, 1–7) (0–12 months) | – |
| Soderburgh et al (56) | ||||||
| 0.5-mg 3MoLD of ranibizumab + sham | 4.0 ± 1.8 | 7.5 | NR | –166 | 8.0 ± 3.3 (0–24 months) | – |
| 0.5-mg 3MoLD of ranibizumab + TTT | 1.0 ± 2.8 | 18.4 | NR | –121 | 6.3 ± 2.8 (0–24 months) | – |
Abbreviations: BCVA, best corrected visual acuity; CI, confidence interval; CRT, central retinal thickness; ETDRS, Early Treatment Diabetic Retinopathy Study; 1MoLD, 1-month loading dose; 3MoLD, 3-month loading dose; NA, not applicable; PDT, photodynamic therapy; PRN, pro re nata (as needed); RF-PDT, reduced fluence photodynamic therapy; SD, standard deviation; SF-PDT, standard fluence photodynamic therapy; TTT, transpupillary thermotherapy.